RESUMO
A multicenter randomized study was performed. One hundred and seventy patients were selected. The patients were 18 years and older. They presented signs and symptoms of genital candidiasis and had positive smear culture for Candida. Eighty five patients were assigned to receive Cicloprox olamine 1%, and eighty five patients were assigned to receive Terconazol 0.8%. The treatment lasted six days with the objective to compare the clinical and antifungal efficiency and safety with both treatments. The result of mixed efficiency (clinical and microbiology) for Cicloprox olamine was 48 cases (62.3%) at the end of the treatment were cured--day 7-; and at the continuation--day 21-42 of them had the same result (55.3%); improvement was seen at the end in 25 cases (32.5%) and at the continuation 21 cases had the same result (27.6%). For Terconazol the result was 45 cases (61.6%) were cured at the end of the treatment, and at the continuation 39 had the same result (57.4%); improvement was seen at the end in 23 cases (31.5%) and at the continuation 22 cases had the same result (32.4%). We conclude that both treatments are effective and well tolerated for genital candidiasis treatment.
Assuntos
Antifúngicos/uso terapêutico , Candidíase Vulvovaginal/tratamento farmacológico , Piridonas/uso terapêutico , Triazóis/uso terapêutico , Adolescente , Adulto , Candidíase Vulvovaginal/microbiologia , Ciclopirox , Feminino , Humanos , Cremes, Espumas e Géis VaginaisRESUMO
At the service of Human Reproduction of the Centro Médico Nacional "20 de Noviembre" ISSSTE from January 94 to August 98, at the first visit, were performed routine screening for antibodies anti-HIV for both partners. Of 672 samples 3 (0.44%) were positive for antibodies anti-HIV with ELISA and two confirmed by Western blot analysis.
Assuntos
Anticorpos Anti-HIV/imunologia , Infecções por HIV/epidemiologia , Soropositividade para HIV/diagnóstico , Adulto , Western Blotting , Ensaio de Imunoadsorção Enzimática , Feminino , Infecções por HIV/imunologia , Humanos , Programas de Rastreamento , México/epidemiologiaRESUMO
Se analizaron 27 tumores intracraneales utilizando sondas moleculares específicas para detectar a los genes CMYC, NMYC y NRAS. Hemos encontrado un importante porcentaje de alteración para estos oncogenes (amplificación y/o rearreglo). Para el oncogen CMYC detectamos el 55 porciento de alteración, 40 porciento para NMYC y el 40 porciento para genes relacionados a RAS. En este estudio fueron incluidos tumores de diferentes diagnósticos histopatológicos en los cuales se detectaron alteraciones combinadas de los genes C y NMYC; este patrón de alteración en la misma muestra tumoral no había sido reportado anteriormente. Además, hemos detectado una alteración frecuente de los genes RAS en adenomas, presentándose amplificación génica así como una expresión incrementada de los mismos. Estos resultados sugieren un papel importante de los genes CMYC, NMYC y RAS en el desarrollo de tumores intracraneales.